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Abstract  
Introduction: It is estimated that 150 million urinary tract infections (UTIs) occur yearly worldwide, resulting in more than 6 billion dollar in direct 
healthcare cost. The etiology of UTIs is predictable, with Escherichia coli, an Enterobacteriaceae being the principal pathogen. Quinolones are 
usually the drug of choice. In this study, we report the resistance pattern of Enterobacteriaceae isolates from UTIs to quinolones among in-patients 
and out-patients at the Yaoundé Reference Hospital in Cameroon. Methods: A cross-sectional descriptive study was carried out for a ten-month 
period. Consecutive clean-catch mid-stream urine samples were collected from 207 in and out-patients. Identification was done using the Api 20E, 
and susceptibility testing using the Kirby Bauer’s disc diffusion method and the MIC was done using the E-test. Results: Out of the 207 isolates, 
58(28.0%) were found to be resistant to all the quinolones used in the study. The resistances observed by species were in the 
order: Enterobacter 4(30.8%); Klebsiella 19(29.7%); Escherichia25 (29.4%); Proteus 2(11.8%); Serratia 4(25.0%). Quinolone resistance 
forEscherichia was 42.9% for In-Patients (IP) and 16.3% for Out-Patient (OP) (P-value = 0.006); Klebsiella 35.9% for IP and 20% for 
OP; Proteus 11.1% for IP and 12.5% for OP; Serratia 18.2% for IP and 40% for OP;Enterobacter 22.2 for IP and 50% for OP. Conclusion: High 
resistance rates to quinolones were observed not only for in-patients but also for out-patients with urinary tract enterobacterial infections. These 
findings demonstrate the importance of antibiotics susceptibility testing in improving quinolones prescription practices in Cameroon. 
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Introduction 
 
Urinary tract infections (UTIs) are common infections. It is 
estimated that 150 million urinary tract infections occur yearly 
worldwide, resulting in more than 6 billion dollar in direct healthcare 
cost [1]. Complicated UTIs include those in patients with stones or 
obstructive uropathies and in patients with catheter-related 
infections. These infections are often associated with nosocomial, 
antibiotic-resistant gram-negative and gram-positive bacteria [2]. 
The etiology of UTIs is predictable, with Escherichia coli an 
Enterobacteriaceae being the principal pathogen [3]. 
  
However, E. coli and other uropathogens are becoming increasingly 
resistant to commonly prescribed antimicrobials, resulting in 
decreased effectiveness of some standard regimes. Quinolones are 
the drug of choice for these infections [4]. Ciprofloxacin, ofloxacin, 
lomefloxacin (Maxaquin), enoxacin (Penetrex), levofloxacin, and 
gatifloxacin have higher renal clearance and greater renal 
concentrations; they are optimal choices for the treatment of 
complicated UTIs [2]. 
  
Quinolones were first introduced into use in 1962 in the form of 
nalidixic acid, which is a completely synthetic agent that in clinical 
concentrations has bactericidal effects on most members of the 
Enterobacteriaceae [5,6]. Just as with other antimicrobials, the 
extensive use or administration of these compounds has led to the 
development of resistance by the bacteria [7-10]. 
  
Little is known about the antimicrobial resistance patterns of 
community-acquired organisms that circulate in developing 
countries where antimicrobials are available without prior 
consultation with a physician most often leading to auto medication 
[11]. 
  
Several surveillance studies from different parts of the world have 
shown that resistance to the fluoroquinolones among 
Enterobactriaceae has increased dramatically worldwide especially 
during the past five years [12]. 
  
In this study, we report the resistance pattern in Enterobacteriaceae 
isolates from urinary tract infections to quinolones among in and 







A total of 207 urine specimens were collected consecutively within a 
period of ten months. Specimens were collected from in and out-
patients at the Yaoundé General Hospital. The collection was done 
by trained medical personnel avoiding contamination. Clean-catch 
mid-stream urine samples were collected from consenting patients. 
The specimens were immediately transported to the laboratory after 
collection and processed. All contaminated urine specimens and all 
patients or children whose guardians refused to fill the consent form 
were excluded from the study. 
  
Isolation and identification 
  
The specimens were inoculated onto Nutrient agar plates using a 
calibrated loop designed to deliver a known volume of 5µl. 
Inoculated plates were then incubated aerobically at 37°C for 24 
hours. After 24 hours, discrete colonies were picked up and gram 
stained. Further sub-culturing for gram negative bacilli was done on 
Eosin Methylene Blue agar to obtain a pure culture and biochemical 
tests were carried out using the Api 20E identification kit in 
accordance with the manufacturer’s manual ((BioMérieux SA, Lyon, 
France). 
  
Antimicrobial susceptibility testing 
  
This was done using the Kirby Bauer Disc diffusion method with 
reference to the Clinical Laboratory Standard Institute (CLSI) 
performance guideline for antimicrobial susceptibility testing [13]. 
Quality was assured by testing the E. coli quality control strain, 
ATCC 25922, in every batch. All zones of inhibition determined were 
within the ranges prescribed by the CLSI. Seven quinolones were 
used; nalidixic acid (NA) and pipemidic acid (PI) of the first 
generation; ciprofloxacin (CIP), norfloxacin (NOR), and ofloxacin 
(OFX) of the second generation; sparfloxacin (SPX) of the third 
generation; and moxifloxacin (MXF) of the fourth generation. 
  
Minimum inhibitory concentration (MIC) 
  
The minimum inhibitory concentration was determined for all the 
isolates that were found to be resistant in the disc diffusion method 
using the e-test. Ciprofloxacin was used. The method was controlled 
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by parallel testing using quality control reference strain (ATCC 




This study received approval from the ethics committee of the 
Faculty of Medicine and Biomedical Sciences of the University of 
Yaoundé 1. All the patients signed the consent form before 






From the 207 urine specimens collected, 118 (57%) isolates were 
from in-patients and 89 (43%) from out patients. The prevalence of 
Enterobacteriaceae in the isolates was in the order: Escherichia 85 
(41.1%); Klebsiella 64(30.9%); 
Proteus 17(8.2%); Serratia 16(7.7%); Enterobacter 13(6.3%); 
others (Citrobacter, Kluyvera, and Morganella) 12(5.9%) 
  
Out of the 207 isolates, 58 (28.0%) were found to be resistant to all 
the quinolones. The resistance observed in each species were in the 
order:Enterobacter 4(30.8%); Klebsiella 19(29.7%); Escherichia 25 
(29.4%); Proteus2(11.8%); Serratia 4(25.0%); others 
4(33.3%) Figure 1. The resistance of each quinolone was NA 
74(35.4%); PI 84 (40.6%); CIP 60(29.0%); OFX 63(30.4); NOR 63 
(30.4%); SPX 62(30.0%) and MXF 61(29.5%) (Shown inFigure 
1) Table 1. 
  
The prevalence of all the Enterobacteriaceae in the in-patients (IP) 
was 118/207(57.0%) and in out-patients (OP) was 89/207(43%) 
(See Table 1). The prevalence of Escherichia was 42/118(35.6%) 
for IP and 43/89(48.3%) for OP, for Klebsiella 39/118(33.1%) for IP 
and 28/89(28%) for OP, for Proteus 9/118(7.6%) for IP and 
8/89(9%) for OP, for Serratia 11/118(9.3%) for IP and 5/89(5.6%) 
for OP, for Enterobacter 9/118(7.6%) for IP and 4/89(4.5%) for 
OPTable 2. 
  
The resistance of all the Enterobacteriaceae in the in-patients (IP) 
was 41/118(34.75%) and in out-patients (OP) was 18/89(20.23%) 
as shown onTable 2. The resistance in Escherichia was 
18/42(42.9%) for IP and 7/43(16.3%) for OP, 
for Klebsiella 14/39(35.9%) for IP and 5/28(17.9%) for OP, 
for Proteus 1/9(11.1%) for IP and 1/8(12.5%) for OP, 
for Serratia2/11(18.2%) for IP and 2/5(40%) for OP, 





In this study we describe the resistance pattern of 
Enterobacteriaceae isolates from urinary tract infections to a 
selected number of quinolones among in and out-patients. The 
overall resistance of the Enterobactericeae to these quinolones was 
high. In African countries with high infectious disease burden, 
formal and informal health systems depend heavily on broad 
spectrum orally-administrable antibacterial. This has caused an 
increase in the resistance of these antibacterial over the years and 
is also affecting even the newer antibacterial like the 
fluoroquinolones [14]. 
  
Quinolones are widely used for the treatment of serious E. 
coli Urinary tract infections (UTIs) and may also be used to treat 
other infections caused by other members of the Enterobacteriaceae 
family. Hence, these high levels of quinolone resistance may lead to 
treatment failure which is of significant concern. These high rates of 
fluoroquinolone resistance observed could also limit treatment 
options especially oral treatment [15,16]. The statistically 
significance difference in resistance between the in and out-patients 
could be due to hospitalized patient being infected by nosocomial 
bacteria. 
  
The strength of this study is the broad population of interest that is 
both the in and out-patients reflecting the circulating resistance. 
There are however some limitations. Our study had a relatively 
small sample size. We also carried out susceptibility testing on only 
a limited numbers of quinolones using only two first generations, 
three second generation, one third generation and one fourth 
generation. This might not be representative of the whole class of 
quinolones which includes several quinolones in each generation. 
  
The overall resistance of 28% to all selected quinolone was slightly 
higher than what was found in other studies carried out in Ghana, 
Greece, the Netherlands and Brazil [16-19]. The resistant rate of the 
isolate from inpatients was higher than that from the outpatients. 
This is similar to what was found in other studies [17]. In our study 
we found that the Escherichia species were the most resistant 
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among the inpatient whereas other studies carried out in Greece 
[17] found Klebsiella to be the most resistant. However, among the 
out-patientKlebsiella was classified as the most resistant just as 
found in other studies. There was a statistically significant difference 
between the overall resistance in inpatients and out-patients just as 
also shown by another study [17]. 
  
Many factors have contributed to this high resistance rates; 
excessive antibiotic prescription is related to a higher prevalence of 
antibiotic resistant bacteria, misuse of antibiotics by health 
professional, unskilled practioners and laypersons (antibiotics can be 
purchased without a prescription). Poor drug quality, unhygienic 
conditions and inadequate surveillance also account for the spread 
of resistant bacteria [20-23]. 
  
Another area to be exploited for future research is the genetic 
diversity and the characterization of these quinolone resistant 
Enterobacteriaceae strains. This will enable us determine the 
prevalence of plasmid-mediated resistance which is a common 
phenomenon among quinolone resistant strains. Further work may 
also identify the prevalence of expanded spectrum beta-lactamases 





High resistance rates to quinolones were observed not only for in-
patients but also for out-patients with urinary tract enterobacterial 
infections. These findings demonstrate the importance of antibiotics 
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Table 1: The prevalence of the enterobacteriaceae isolates in hospitalized and community patients 
Species In-patients (N=118) Out-patients (N=89) p-value 
  No % No %   
Escherichia 42 35.6% 43 48.3% 0.066 
Klebsiella 39 33.1% 25 28.1% 0.445 
Proteus 9 7.6% 8 9.0% 0.764 
Serratia 11 9.3% 5 5.6% 0.323 
Enterobacter 9 7.6% 4 4.5% 0.358 
others 8 6.8% 4 4.5% 0.3 
Total 118 57.0% 89 43% 0.765 
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  p-value 
  No Resistant % No resistant %   
Escherichia 18 42.9% 7 16.3% 0.006 
Klebsiella 14 35.9% 5 17.9% 0.13 
Proteus 1 11.1% 1 12.5% 0.335 
Serratia 2 18.2% 2 40% 1.0 
Enterobacter 2 22.2% 2 50% 1.0 
others 4 50% 1 25% >0.3 





Figure 1: The resistance rate of the enterobacteriaceae isolates to the selected quinolones 
 
